IMPORTANT SAFETY INFORMATION
BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES
- Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
- Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids as needed.
- TECARTUS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program.
Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred
following treatment with TECARTUS. CRS occurred in 91% (75/82) of patients with MCL,
including ≥ Grade 3 CRS in 18% of patients. CRS occurred in 92% (72/78) of patients with ALL,
including ≥ Grade 3 CRS in 26% of patients. The median time to onset of CRS was 3 days
(range: 1 to 13 days) and the median duration of CRS was 10 days (range: 1 to 50 days) for
patients with MCL. Three patients with ALL had ongoing CRS events at the time of death. The
median time to onset of CRS was 5 days (range: 1 to 12 days) and the median duration of CRS
was 8 days (range: 2 to 63 days) for patients with ALL. Among patients with CRS, the key
manifestations (>10%) were similar in MCL and ALL and included fever (93%), hypotension
(62%), tachycardia (59%), chills (32%), hypoxia (31%), headache (21%), fatigue (20%), and
nausea (13%). Serious events associated with CRS in MCL and ALL combined (≥ 2%) included
hypotension, fever, hypoxia, tachycardia, and dyspnea.
Ensure that a minimum of 2 doses of tocilizumab are available for each patient prior to infusion of TECARTUS. Following infusion, monitor patients for signs and symptoms of CRS daily for at least 7 days for patients with MCL and at least 14 days for patients with ALL at the certified healthcare facility, and for 4 weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.
Neurologic Toxicities, including those that were fatal or life-threatening, occurred following
treatment with TECARTUS. Neurologic events occurred in 81% (66/82) of patients with MCL,
including ≥ Grade 3 in 37% of patients. The median time to onset for neurologic events was 6
days (range: 1 to 32 days) with a median duration of 21 days (range: 2 to 454 days) in patients
with MCL. Neurologic events occurred in 87% (68/78) of patients with ALL, including ≥ Grade 3
in 35% of patients. The median time to onset for neurologic events was 7 days (range: 1 to 51
days) with a median duration of 15 days (range: 1 to 397 days) in patients with ALL. The onset
of neurologic events can be concurrent with CRS, following resolution of CRS, or in the absence
of CRS. 91% of all treated patients experienced the first CRS or neurological event within the
first 7 days after TECARTUS infusion.
The most common neurologic events (>10%) were similar in MCL and ALL and included
encephalopathy (57%), headache (37%), tremor (34%), confusional state (26%), aphasia
(23%), delirium (17%), dizziness (15%), anxiety (14%), and agitation (12%). Serious events
including encephalopathy, aphasia, confusional state, and seizures occurred after treatment
with TECARTUS. Monitor patients daily for at least 7 days for patients with MCL and at least 14
days for patients with ALL at the certified healthcare facility and for 4 weeks following infusion
for signs and symptoms of neurologic toxicities and treat promptly.
REMS Program: Because of the risk of CRS and neurologic toxicities, TECARTUS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program which requires that:
- Healthcare facilities that dispense and administer TECARTUS must be enrolled in and comply with the REMS requirements. Certified healthcare facilities must have on-site, immediate access to tocilizumab, and ensure that a minimum of 2 doses of tocilizumab are available for each patient for infusion within 2 hours after TECARTUS infusion, if needed for treatment of CRS.
- Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer TECARTUS are trained in the management of CRS and neurologic toxicities. Further information is available at www.YescartaTecartusREMS.com or 1-844-454-KITE (5483).
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including life-threatening reactions, occurred following treatment with TECARTUS. HLH/MAS
occurred in 4% (3/78) of patients with ALL. Two patients experienced Grade 3 events and 1
patient experienced a Grade 4 event. The median time to onset for HLH/MAS was 8 days
(range: 6 to 9 days) with a median duration of 5 days (range: 2 to 8 days). All 3 patients with
HLH/MAS had concurrent CRS symptoms and neurologic events after TECARTUS infusion.
Treatment of HLH/MAS should be administered per institutional standards.
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may
occur due to dimethyl sulfoxide (DMSO) or residual gentamicin in TECARTUS.
Severe Infections: Severe or life-threatening infections occurred in patients after TECARTUS
infusion. Infections (all grades) occurred in 56% (46/82) of patients with MCL and 44% (34/78)
of patients with ALL. Grade 3 or higher infections, including bacterial, viral, and fungal
infections, occurred in 30% of patients with ALL and MCL. TECARTUS should not be
administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer
prophylactic antimicrobials according to local guidelines.
Febrile neutropenia was observed in 6% of patients with MCL and 35% of patients with ALL
after TECARTUS infusion and may be concurrent with CRS. In the event of febrile neutropenia,
evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive
care as medically indicated.
In immunosuppressed patients, life-threatening and fatal opportunistic infections have been
reported. The possibility of rare infectious etiologies (e.g., fungal and viral infections such as
HHV-6 and progressive multifocal leukoencephalopathy) should be considered in patients with
neurologic events and appropriate diagnostic evaluations should be performed.
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic
failure, and death, can occur in patients treated with drugs directed against B cells. Perform
screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells
Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following
lymphodepleting chemotherapy and TECARTUS infusion. In patients with MCL, Grade 3 or
higher cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 55%
(45/82) of patients and included thrombocytopenia (38%), neutropenia (37%), and anemia
(17%). In patients with ALL who were responders to TECARTUS treatment, Grade 3 or higher
cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 20% (7/35) of the
patients and included neutropenia (12%) and thrombocytopenia (12%); Grade 3 or higher
cytopenias not resolved by Day 60 following TECARTUS infusion occurred in 11% (4/35) of the
patients and included neutropenia (9%) and thrombocytopenia (6%). Monitor blood counts after
Hypogammaglobulinemia and B-cell aplasia can occur in patients receiving treatment with
TECARTUS. Hypogammaglobulinemia was reported in 16% (13/82) of patients with MCL and
9% (7/78) of patients with ALL. Monitor immunoglobulin levels after treatment with TECARTUS
and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin
replacement. The safety of immunization with live viral vaccines during or following TECARTUS
treatment has not been studied. Vaccination with live virus vaccines is not recommended for at
least 6 weeks prior to the start of lymphodepleting chemotherapy, during treatment, and until
immune recovery following treatment with TECARTUS.
Secondary Malignancies may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.
Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events,
including altered mental status or seizures, patients are at risk for altered or decreased
consciousness or coordination in the 8 weeks following TECARTUS infusion. Advise patients to
refrain from driving and engaging in hazardous activities, such as operating heavy or potentially
dangerous machinery, during this period.
Adverse Reactions: The most common adverse reactions (incidence ≥ 20%) in MCL patients
were fever, CRS, hypotension, encephalopathy, fatigue, tachycardia, arrhythmia, infection with
pathogen unspecified, chills, hypoxia, cough, tremor, musculoskeletal pain, headache, nausea,
edema, motor dysfunction, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia,
pleural effusion, and aphasia.
The most common adverse reactions (incidence ≥ 20%) in ALL patients were fever, cytokine
release syndrome, hypotension, encephalopathy, tachycardia, nausea, chills, headache,
fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor,
infection with pathogen unspecified, constipation, decreased appetite, and vomiting.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.